Icon Bioscience Announces Pivotal Phase 3 Clinical Data Demonstrates Exceptional Efficacy of IBI-10090 in Reducing Inflammation Associated with Cataract Surgery
SUNNYVALE, Calif.--(BUSINESS WIRE)--Phase 3 trial data showed that IBI-10090 is highly effective in treating inflammation post cataract surgery.
